Eutilex.Co.Ltd - Asset Resilience Ratio

Latest as of September 2025: 0.11%

Eutilex.Co.Ltd (263050) has an Asset Resilience Ratio of 0.11% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Eutilex.Co.Ltd carry for a breakdown of total debt and financial obligations.

Liquid Assets

₩54.65 Million

≈ $37.04K USD Cash + Short-term Investments

Total Assets

₩51.00 Billion

≈ $34.56 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how Eutilex.Co.Ltd's Asset Resilience Ratio has changed over time. See 263050 total equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Eutilex.Co.Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Eutilex.Co.Ltd.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩54.65 Million	0.11%
Total Liquid Assets	₩54.65 Million	0.11%

Asset Resilience Insights

Limited Liquidity: Eutilex.Co.Ltd maintains only 0.11% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Eutilex.Co.Ltd Industry Peers by Asset Resilience Ratio

Compare Eutilex.Co.Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Royalty Pharma Plc NASDAQ:RPRX	Biotechnology	0.10%
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	3.28%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	4.52%
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	35.56%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Jiangsu Aidea Pharmaceutical Co Ltd SHG:688488	Biotechnology	4.35%

Annual Asset Resilience Ratio for Eutilex.Co.Ltd (2016–2024)

The table below shows the annual Asset Resilience Ratio data for Eutilex.Co.Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	29.55%	₩19.66 Billion ≈ $13.32 Million	₩66.51 Billion ≈ $45.07 Million	-23.04pp
2023-12-31	52.59%	₩38.24 Billion ≈ $25.91 Million	₩72.70 Billion ≈ $49.27 Million	-11.90pp
2022-12-31	64.49%	₩67.37 Billion ≈ $45.66 Million	₩104.46 Billion ≈ $70.79 Million	+0.59pp
2021-12-31	63.91%	₩72.65 Billion ≈ $49.23 Million	₩113.68 Billion ≈ $77.04 Million	-0.27pp
2020-12-31	64.18%	₩67.73 Billion ≈ $45.90 Million	₩105.54 Billion ≈ $71.52 Million	+10.77pp
2019-12-31	53.41%	₩40.59 Billion ≈ $27.51 Million	₩76.01 Billion ≈ $51.51 Million	-20.24pp
2018-12-31	73.65%	₩62.65 Billion ≈ $42.46 Million	₩85.06 Billion ≈ $57.65 Million	+3.80pp
2017-12-31	69.85%	₩40.85 Billion ≈ $27.69 Million	₩58.49 Billion ≈ $39.64 Million	+12.00pp
2016-12-31	57.85%	₩18.25 Billion ≈ $12.37 Million	₩31.55 Billion ≈ $21.38 Million	--

pp = percentage points

About Eutilex.Co.Ltd

KQ:263050 Korea Biotechnology

Market Cap

$23.94 Million

₩35.32 Billion KRW

Market Cap Rank

#24464 Global

#1805 in Korea

Share Price

₩959.00

Change (1 day)

+29.95%

52-Week Range

₩683.00 - ₩2740.00

All Time High

₩41553.86